On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
-
REGULATORY LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
-
BUSINESS Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
-
REGULATORY LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
-
BUSINESS AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
-
ORGANIZATION Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
-
BUSINESS Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
-
REGULATORY Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
-
REGULATORY LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
-
BUSINESS AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
-
REGULATORY Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
-
BUSINESS Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
-
BUSINESS Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
-
BUSINESS LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
-
REGULATORY PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
-
REGULATORY Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
-
REGULATORY R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
-
REGULATORY Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
-
REGULATORY FY2026 Reform Roadmap Keeps Key Drug Pricing Issues on Ice, Snubs Many Industry Requests: Chuikyo
December 4, 2025
-
REGULATORY Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
December 3, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…